Wanted this level to buy! |
 Best to ignore current performance in share price as there's plenty of potential positive newsflow fast approaching that could add significant value, and looks like the BioWin, Wallonia Biotech's have multiple international events throughout the year. Gla holders:-)
BioWin
Sarcopenia is a geriatric syndrome that causes a decline in muscle mass. Living with sarcopenia significantly affects quality of life and frequently leads to falls and fractures, but especially affects mobility. This loss of mobility leads to an increased risk of metabolic, cardiovascular and cancer pathologies. With the ageing of the population, sarcopenia has become a major public health problem. It is estimated that between a quarter and a half of the population aged 65 or over currently suffer from it. In 2019, the cost of hospitalisation alone for patients in this age bracket was over $19 billion, not to mention the cost of associated treatments, which are currently only palliative, as no targeted treatment for this pathology is currently available.
In partnership with ULiège, Revatis has demonstrated that it is possible to obtain muscle-derived stem cells (mdMSCs), in quality and quantity, from elderly human and equine individuals. Revatis has already obtained mdMSCs from horses with pathological conditions similar to human sarcopenia. Moreover, these mdMSCs can be easily transfected, secrete large quantities of extracellular vesicles and are capable of transferring mitochondria.
Genflow Biosciences is interested in age-related diseases, and in particular in a variant of the gene encoding sirtuin 6 (SIRT6c), identified only in a population of centenarians. This SIRT6 gene is involved in regulating mitochondrial function, a function impaired in sarcopenia.
The idea was therefore to combine these data to develop an innovative drug therapy using modified mdMCSs expressing the SIRT6c variant to improve the function of deficient muscle cells. Cells will be transfected with the gene encoding SIRT6c, potentially in combination with other sirtuin family genes. This drug will target mitochondrial dysfunction, which plays a major role in the pathophysiology of sarcopenia. |
Watch this space...Gl ;-) |
Aye that's why everyone is selling and no one is buying 😂😂 |
Lol, on the contrary, Genflow is all set for some stellar UPside this year with plenty of Big news, fast approaching!!! Gl :-) |
Biotech & Longevity: The Future of Health, Investments & Human Lifespan 🧬
Feb 24, 2025
The biotech and longevity 🏥 sectors are on an unstoppable growth trajectory, fueled by breakthrough innovations, surging investments, and an aging global population 🏃♂;️💊. With the promise of longer, healthier lives ahead, this space has become a prime target for venture capitalists, big pharma, and tech giants alike.
📈 1. Sector Performance: A Multi-Billion-Dollar Industry on the Rise
The global biotechnology market 💰 has been expanding at an impressive rate. In 2024, it was valued at $483 billion, and it's projected to surpass $546 billion by the end of 2025 📊. This 13% compound annual growth rate (CAGR) is driven by innovations in gene therapy, precision medicine, and AI-driven drug discovery 🤖.
Source: Global Biotech Industry Outlook 2025
🔹 Longevity biotech – an industry dedicated to extending healthy lifespan ⏳ – is booming! The sector is projected to hit $600 billion by 2025 🚀, with major growth areas including:
✔️ Gene editing 🧬 (CRISPR, epigenetic reprogramming)
✔️ Regenerative medicine 🦠 (stem cells, tissue engineering)
✔️ Anti-aging therapeutics 🔄 (senolytics, cellular rejuvenation)
📌 Key Trend: The global aging population 👴📉 is a driving force behind this growth, with over 2.1 billion people expected to be 60+ by 2050. This has created massive demand for longevity-related solutions.
💰 2. Investment Growth: Big Money Meets Biotech
In 2024 alone, biotech and longevity startups raised record-breaking funding:
💵 $45 billion in venture capital flowed into the sector 🌊
🏦 Institutional investors & hedge funds doubled their stakes 📈
📑 M&A activity soared, as companies rushed to acquire cutting-edge technologies 🎯
💡 Major Deals & Investments:
Altos Labs 🏢 (funded by Jeff Bezos & Yuri Milner) secured $3 billion for cellular rejuvenation research 🦠.
Calico (Google-backed) invested in AI-powered drug discovery 🤖💊.
2025 J.P. Morgan Healthcare Conference saw $300 billion worth of deals, focusing on biotech M&As 🤝.
🚀 Why the Hype? Aging is now being treated as a disease, and investors believe they can extend human healthspan by targeting its root causes. That’s a trillion-dollar opportunity!
🏥 3. Healthcare Innovations: The Science of Longevity
🔬 Three Game-Changing Innovations:
1️⃣ AI-Driven Drug Discovery 🤖💊
AI is slashing drug development timelines ⏳ by 50-75%, making treatments faster and cheaper. Insilico Medicine and DeepMind's AlphaFold are leading the charge!
2️⃣ Gene Editing & CRISPR 🧬
Biotech startups are using CRISPR-Cas9 to reverse aging at the genetic level 🔄. Companies like Verve Therapeutics & Editas Medicine are pioneering gene therapies for longevity.
3️⃣ Senolytics & Cellular Rejuvenation 🦠
Anti-aging drugs are hitting clinical trials 🚑. Unity Biotechnology & Rejuvenate Bio are testing senolytic therapies to eliminate aging cells and prolong life.
🚀 4. Key Players & Startups Dominating the Space
💡 Biotech Unicorns & Market Leaders:
Altos Labs 🦄 (Cellular rejuvenation)
Calico (Alphabet/Google) 🤖 (AI-driven longevity research)
Juvena Therapeutics 🔬 (AI-based regenerative therapies)
Life Biosciences 🏥 (Mitochondrial repair for longevity)
Retro Biosciences 🦠 (Developing age-reversal therapies)
👀 Pharma Giants Betting Big:
Pfizer 💊 investing billions in gene therapy
AstraZeneca 🧬 leading AI-powered biotech R&D
Novartis 🔄 pioneering anti-aging clinical trials
🔗 Further Reading & Graphics on Biotech & Longevity
📊 Recent Market Reports & Infographics
Global Biotech Industry Outlook 2025 📈
Biotech Market Forecast: Top Trends for Biotech in 2025 🧬
2025 Preview: What Does the Year Ahead Hold for Pharma? 🏥
The biotech & longevity revolution is happening faster than ever before. With AI, gene editing, and regenerative medicine at the forefront, the dream of living healthier, longer lives is within reach 🚀.
👉 Are you ready to invest in the future of longevity? |
Sirt6, a panacea for multiple disease targets, aging, longevity and healthspan. Gl :-)
UTMB Study Identifies an Anti-Aging Protein as Key to Preventing Vision Loss in Glaucoma
September 20, 2024
Researchers at the University of Texas Medical Branch recently made a breakthrough in understanding how aging contributes to glaucoma, the second leading cause of irreversible blindness worldwide. Their latest study published in Molecular Therapy highlights the crucial role of the anti-aging protein, Sirt6, for preventing vision loss in millions affected by the disease.
"Our findings demonstrate that Sirt6 is essential for protecting retinal ganglion cells from aging and glaucoma-induced damage," said senior author Hua Liu, associate professor at the Department of Ophthalmology and Visual Sciences at UTMB. "When Sirt6 was removed in our animal models, we saw a significant increase in retinal cell loss, leading to vision impairment. This suggests that Sirt6 not only regulates the aging process but also plays a vital role in maintaining vision."
This research represents the first comprehensive study of anti-aging mechanism in glaucoma by experiments in multiple mouse models that collectively encompass diverse aspects of glaucomatous pathology.
"Therapeutically targeting Sirt6 offers a promising new avenue for glaucoma treatment, especially for cases that do not respond to traditional treatments aimed at reducing eye pressure," said co-senior author Wenbo Zhang, professor at the Department of Ophthalmology and Visual Sciences at UTMB. "This could be a game-changer in how we approach this disease." |
Another great interview from Eric, and very interesting he mentions Glaucoma as a target ( for the first time as far as I know ) and so maybe more detail to follow, and also looking forward to an announcement on the Dog study, "expected VERY soon on Sirt6's potential on life extension in Dogs and an angle of loss of muscle function in aging dogs"...Excitement building, Woof Woof!!!, and hopefully full market appreciation to follow. In Eric we trust!!! :-))) |
News on the Dog Trial "expected very soon" according to Eric. Gla ;-) |
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,833 followers
19h
🧬 Big things are happening at Genflow Biosciences (LON:GENF) (OTCQB:GENFF)!
The European Patent Office has advanced #GENF's exclusive, out-licensed patent for "Variants of #SIRT6 for Use in Preventing and/or Treating Age-Related Diseases."
This marks a critical step toward securing market-specific protections across Europe - reinforcing our leadership in longevity focused #biotech.
Read the release here:
#GENFF #Healthspan #Longevity
............
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,833 followers
18h
🧬 What is #MASH, and why does it matter?
Metabolic dysfunction associated steatohepatitis (MASH), formerly known as NASH, is a progressive #LiverDisease caused by fat buildup and #inflammation. It can lead to:
🔹 Fibrosis (scarring of the liver)
🔹 #Cirrhosis (severe liver damage)
🔹 Liver failure or cancer
With no approved treatments available, MASH is a growing global health concern. At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we are working to change that by harnessing the power of the SIRT6 gene, a key longevity regulator involved in DNA repair and metabolic health.
Our lead drug candidate, GF-1002, is designed to address MASH by delivering a centenarian variant of #SIRT6 to the liver. We’re pioneering new frontiers in gene therapy to tackle aging related diseases at their root.
Stay tuned as we advance - the future of liver health is evolving! 🧬
#GENF #GENFF #Healthspan |
More fool them, cheap shares are being accumulated to tight hands for bigger and better things to come....Watch this space!!! Gl :-) |
Cor,RTO coming there and it's about to blow! |
Lol, think I'll stick with Genflow thank you very much. Multiple positive newsflow expected this year!!! Gl :-) |
Miri flying,this going nowhere, also CWR a good pick up if you have funds,drop well overdone on that. |
SP going nowhere as usual,I sold earlier as no interest here from investors,I all in Miri now. |
Great news and undoubtedly strenghtens and increases the chances of a JV with Major Pharma and the following highlights the ongoing research by Genflow's academic calloborative partners who receied $13.6m in funding towards Sirt6 R & D in January 2024. Gla ;-)
Einstein Scientists Lead Groundbreaking Search for Genetic Keys to Long, Healthy Life
Rare gene variants in centenarians discovered; $13.6 million grant will expand research.
January 16, 2024
Finding How Variants Function
The saga of a gene called SIRT6 illustrates how Dr. Vijg and his colleagues—a multicenter scientific consortium conducting four different projects—are working collaboratively to translate gene sequencing data into drugs for combating age-related diseases.
Project one of the consortium, which is involved with studying gene sequences, paid special attention to the SIRT6 gene. Vera Gorbunova, PhD, Project Leader, University of Rochester, had earlier discovered that SIRT6 codes for an enzyme associated with DNA repair, and other research indicates it protects against aging and disease. For example, SIRT6 expression is reduced in the brains of Alzheimer’s patients, and overexpressing the gene in roundworms and mice significantly extended their lifespans. Yousin Suh, PhD, Adjunct Professor, Genetics, Medicine, Albert Einstein College of Medicine, and Project Member, Columbia University, then found that a variant of SIRT6, centSIRT6, occurred twice as often among the study’s centenarians compared with control-group participants. |
RNS Number : 7707X
Genflow Biosciences PLC
20 February 2025
20 February 2025
Genflow Biosciences Plc
Genflow Biosciences Advances SIRT6 Variant Patent Application Following Positive Search Report from European Patent Office
Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce today that its exclusive, out-licensed patent application for "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases" has successfully progressed through the Supplementary European Search Report without further questions from the European Patent Office (EPO).
The European patent application (EP 22 808 414.1), originally filed on May 13, 2022, by the University of Rochester, The Trustees of Columbia University in the City of New York, and the Albert Einstein College of Medicine, marks a significant step in securing protection for SIRT6 variants, a promising innovation in age-related disease therapeutics. The SIRT6 gene/protein, is known for its critical role in DNA repair, metabolism, and longevity.
Following the EPO's assessment, no further questions were raised, allowing the application to progress to the national phase of the patent process, a critical stage in securing market-specific protections across Europe.
Key Details:
· Application Title: Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases
· Applicants: University of Rochester; The Trustees of Columbia University in the City of New York; Albert Einstein College of Medicine
· Patent Application Number: EP 22 808 414.1
· Filing Date: 13 May 2022
· Result: The application met all requirements of the European Patent Convention (EPC).
· Next Steps: Genflow is preparing its intention to advance the application required by 7 July 2025.
Genflow remains focused on advancing its longevity-focused therapeutic pipeline and will continue to update stakeholders as the patent application progresses.
Dr. Eric Leire, CEO of Genflow commented: "This positive outcome represents a significant step forward in securing broad intellectual property protection for our innovative work on SIRT6 variants. This milestone strengthens our position in SIRT6-based therapeutics and accelerates our mission to develop effective treatments for age-related diseases." |
Courtesy of Porter on Lse, let's hope Genflow are mentioned for good reason. Gla :-)
naturalX secures €100m to fuel the future of consumer health in Europe
The new fund supports of NaturalX, which has its first closing at €100m, supports proactive healthcare, filling a market gap as consumers take control of their own health journey.
...
While the US market has seen the rise of consumer-centric healthcare champions like Hims/Hers, Headspace, and Function Health, Europe’s market remains underserved, according to naturalX. The venture capitalists’ €100m fund is dedicated to support European consumer health-focussed start-up companies that are active in sleep, mental health, probiotics and gut health, prevention, and longevity such as UK-based clock.bio, Storm Therapeutics, and Genflow Biosciences.
Focussed on Series-A investments, typical first investments will range from €3-5m, with up to €10m available per company. naturalX can act as either lead investor or co-investor, targeting consumer health startups across Europe with selected investments in North America. |
Eric Verdin, MD, president and CEO of the Buck Institute for Research on Aging in Novato, California, pointed out that due to scientific advances, "we live longer but not healthier ... Our mission is to eliminate the threat of chronic disease by addressing the aging process itself." And just as vaccines and antibiotics revolutionized medicine in the past, "aging is the next great frontier in preventive healthcare," he said. "Investing in aging research must be a priority." |
Ps looks like Eric Verdin's testimony to the US senate, CEO of the Buck Institute, who sits on Genflow’s Scientific Advisory Board, got his message across. Gla :-)
BREAKING: NIH admits funding freeze is illegal, will resume issuing grants
On Monday afternoon, Popular Information broke the news that the National Institutes of Health (NIH) had frozen virtually all grant funding in violation of two federal court orders. The grants were frozen pending a review for compliance with President Trump's executive orders, including those targeting spending related to Diversity, Equity, and Inclusion (DEI). Our story was based on information from an NIH official who spoke on the condition of anonymity and internal NIH correspondence confirming the freeze.
David Super, a professor at Georgetown University Law Center and an expert on administrative law, told Popular Information that the Trump administration was "in contempt of court" and the continued funding freeze at NIH was "completely unlawful."
......
Now, staff is finally authorized to issue new and continuing grants under existing "funding policies." The grants will be issued "with “the previously approved negotiated indirect cost rates” and not0 the 15% indirect cost cap the Trump administration was seeking to impose. The cap on indirect costs would be a severe blow the biomedical research in the United States.
This means critical funding for research on everything from cancer treatments to heart disease prevention to stroke interventions will resume. |
WHO WE ARE
Pioneering Novel Gene Therapeutics for a Longer, Healthier Life
MISSION: aging is underlying risk factor for disease, and our aim is to delivegene therapeutics that potentially halt or slow the aging process in humans and dogs
SIRT6 GENE: longevity protein that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases
PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene for treatment of MASH
SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech
ROBUST PIPELINE: advancing multiple development programs
over 24 months: MASH, Sarcopenia, Werner and life extension of dogs
SIRT6: REPAIRING DNA
SIRT6 gene/protein repairs DNA damage (especially double strand breaks (DSB)) and prevents senescence of our cells
SIRT6 gene codes for SIRT6 protein
Stronger SIRT6: Longer lifespan
The Ability of SIRT6 to stimulate DSB repair corelates with maximum lifespan (MLS) in rodents
5 Amino Acids determine the differential activities of SIRT6
FOCUS ON CENTENARIAN SIRT6
SIRT6 centenarian variant gene has more efficient DNA repair properties
MASH PROGRAM
Affects est. 35 million people globally
• Increasing prevalence
• Leading cause of chronic liver disease and liver transplant
Significant unmet medical need
Clear regulatory accelerated development pathway.
EMA and FDA guidelines accept:
✓ Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH
✓ Histological changes are achievable within a 12-18-month time-frame
✓ Placebo control
✓ Conditional fast-track approval
EXOSOME DELIVERY SYSTEM: SAFE AND COST-EFFECTIVE
Genflow’s patent-pending technology has already been tested in several preclinical studies
ADVANTAGES: EXOSOME DELIVERY
Exo-AAV can mediate efficient, specific, and more durable SIRT6 expression in liver compared to conventional AAV
GROWING IP PORTFOLIO
Provisional patent application in 2023 for editing SIRT6 gene, linked to longevity and age-related diseases
EXPANDED MARKET
Awarded to new grants in 2023 & 2024 expanding research pipeline and size of therapeutic markets
GF-1002
Undertaking key Investigational New Drug (IND) -enabling development activities to help define pharmacological and toxicological properties and potential benefit to NASH patients
GF-1003
Commencing preliminary discussions with the European Medicines Agency (EMA) on Mechanism of Action (MoA) data for Orphan Drug Application (ODA) targeting Werner Syndrome
LARGE MARKET OPPORTUNITY
NASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication
LONG LIFE IP
2 patent families SIRT6 centenarian and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)
GENE DELIVERY SYSTEMS
Proprietary innovative gene delivery systems: exo-AAV, mRNA exosomes, LNPs Centenarian variant of SIRT6 gene
GF-1002 and GF-1003
Multiple key clinical and regulatory milestones expected in next 18 months
Undervalued stock opportunity; Potential acquisition by pharmaceutical partner |
A similar deal for Genflow more than possible. Gla :-) |
OliX strikes $630 million deal with Lilly for obesity and liver disease drug
2025-02-10
OliX Pharmaceuticals, a Korean biotech company specializing in RNA interference (RNAi) therapies, has signed an exclusive global licensing deal with Eli Lilly worth up to $630 million.
The agreement, announced last Friday, grants Lilly the rights to develop and commercialize OLX75016, an experimental RNAi-based treatment targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
OliX will continue conducting phase 1 clinical trials of OLX75016 in Australia, after which Lilly will take over subsequent development and commercialization. OliX will receive upfront and milestone-based payments tied to clinical progress. While financial specifics remain undisclosed, the company stated that all payments are non-refundable. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
